BreezeBio closed a $60 million financing to advance its polymer nanoparticle delivery platform and initiate clinical testing of its lead mRNA program for diabetes. The company, which refocused from purely delivery tooling to developing its own therapeutic candidates, said the funds will support IND‑enabling studies and early‑phase trials for a tolerance‑inducing candidate targeting Type 1 diabetes. Investors backed the move amid rising interest in nonviral, polymeric delivery solutions for nucleic acid medicines. BreezeBio positions its platform as an alternative to lipid nanoparticles with claims of improved stability and tissue targeting, aiming to address both manufacturing scalability and safety considerations for repeated dosing in chronic conditions.